China Medical System Holdings Limited (CMS) disclosed a share repurchase of 0.50 million ordinary shares on 24 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The purchase was executed within a price range of HK$9.94–HK$10.22 per share, resulting in a volume-weighted average cost of HK$10.12 per share and a total outlay of approximately HK$5.06 million.

Following the transaction, CMS’s issued share capital outstanding (excluding treasury shares) decreased to 2.43 billion shares, down from 2.43 billion shares prior to the buyback. Treasury shares increased from 5.90 million to 6.40 million, while the company’s total issued share count remained unchanged at 2.44 billion shares.

The repurchase forms part of the mandate approved by shareholders on 23 April 2026, which authorises CMS to buy back up to 243.95 million shares. Cumulative purchases under this mandate now stand at 6.40 million shares, representing 0.26% of the issued share base as of the mandate date.

Under Hong Kong Stock Exchange rules, CMS is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 24 July 2026.

The board confirms that the repurchase complied with all relevant listing rules and regulatory requirements and that full consideration has been settled.